Revolution Medicines, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $162.69
- 52-Week Range
- $69.50 – $224.31
- Market Cap
- $34.57B
- P/E (TTM)
- —
- EPS (TTM)
- -9.13
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 14.39
- PEG Ratio
- —
- Return on Equity
- -93.56%
- Return on Assets
- -32.13%
- Gross Margin
- 0.00%
- Operating Margin
- -852.98%
- Profit Margin
- 0.00%
- Current Ratio
- 8.36
- Debt/Equity
- 0.50
- Total Debt
- $1.21B
- Free Cash Flow
- $-886.29M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $32.13B
Market Snapshot
About
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company focuses on creating innovative small molecule drugs that address difficult-to-treat cancers driven by RAS mutations, one of the most common oncogenic drivers. Revolution Medicines utilizes a structure-based drug design platform to advance multiple programs through clinical development.